PD 198306

• Description:

  PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H228, H315, H319

• Target:

  MEK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pd-198306.html

• Purity:

  99.75

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  O=C(NOCC1CC1)C(C=C(F)C(F)=C2F)=C2NC3=C(C=C(I)C=C3)C

• Molecular Formula:

  C18H16F3IN2O2

• Molecular Weight:

  476.23

• Precautions:

  H228, H315, H319

• References & Citations:

  [1]A Ciruela, et al. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003 Mar;138 (5) :751-6. |[2]Benoit Besson, et al. Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection. mSphere. 2019 May 22;4 (3) :e00047-19.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  MEK

• CAS Number:

  [212631-61-3]